Navigation Links
InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
Date:2/2/2012

BRISBANE, Calif., Feb. 2, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its fourth quarter and full year 2011 financial results at the close of the U.S. markets on Thursday, February 9, 2012.  A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

Interested investors and others may participate in the conference call by dialing 800-891-8257 (U.S.) or +1-212-271-4651 (international), conference ID# 21576715.  A replay of the webcast and teleconference will be available on the company's website approximately three hours after the call.

To access the live webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 800-633-8284 (U.S.) or +1 402-977-9140 (international), and entering the conference ID# 21576715.  

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2020)... ... May 29, 2020 , ... The Conference Forum is ... solely dedicated to the unique role of the Chief Medical Officer in the ... responsibilities, problem-solving, best practices and career development of CMOs and Heads of R&D ...
(Date:5/28/2020)... ... May 28, 2020 , ... The Security Industry Association (SIA) and ... winners of the Women in Biometrics Awards – a globally recognized program ... Update and the SIA Women in Security Forum . The honorees will ...
(Date:5/21/2020)... , ... May 21, 2020 , ... ... clinical trials will cause long-term harm , Contrary to conventional wisdom that says ... study finds many companies will emerge from the pandemic commercially weaker, dealing ...
(Date:5/21/2020)... ... May 19, 2020 , ... Eaton Square is pleased to ... Popper and Company, a biotechnology and medical technology-focused strategy and M&A advisory firm. , ... the United States, linking US and Asia Pacific healthcare innovators with capital and investors. ...
Breaking Biology Technology:
(Date:5/28/2020)... ... May 28, 2020 , ... ... a new enzyme solution for adjunct liquefaction: AMYLEX® 6T. The innovative enzyme ... to expand into new segments with locally-sourced raw materials, improve productivity, maximize ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... IntegritySM technology-based services specializing in background and medical screening, announces the launch ... planning and keeping their workforce safe. The new service is provided by ...
(Date:5/21/2020)... ... May 21, 2020 , ... Agility Orthopedics, home to dedicated ... area, is pleased to announce a partnership with Dallas-based Simple Interact to further ... the area, Agility Orthopedics is focused on speeding up patient workflows to enhance ...
Breaking Biology News(10 mins):